The CRISPR safety reset: what Intellia’s lifted FDA hold really means for one-and-done gene editing
On March 2, 2026, the U.S. Food and Drug Administration
A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see
Early data from a tiny trial suggest that a single
Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause
Standfirst: A hospitalised patient with a Hy’s-law-like profile has forced
Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030?
Beyond CRISPR Hype Gene editing has promised to revolutionize medicine,
Gene Editing for Everyone: CRISPRware and the Open-Source Biotech Revolution
CRISPRware Signals a New Era in Democratized Gene Editing In
Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market
High cholesterol has long been a silent threat lurking in
CRISPR-Cas9 Enhances Rice Yields Without Introducing Foreign DNA
This study explores the use of CRISPR-Cas9 technology to increase
Innovative Breakthrough in Genomics: Profluent’s OpenCRISPR-1 Revolutionizes Human Genome Editing
In a groundbreaking achievement, the biotechnology firm Profluent has successfully
MOST POPULAR
